| 词条 | Foresite Capital |
| 释义 |
| name=Foresite Capital | industry=Venture capital, growth equity | founded=2011 | founder=Jim Tananbaum, CEO | website={{URL|http://www.foresitecapital.com/}} }}Foresite Capital is an American venture capital and growth equity firm.[1][2] The company has offices in San Francisco and New York. As of May 2017, the company had raised three funds, Foresite Capital Fund I, II and III.[1] HistoryForesite Capital was founded in 2011 by Jim Tananbaum, co-founder of Theravance,[3][4] who became CEO of the company.[5] Foresite Capital raised its $100 million Fund I in 2013.[6][7] Foresite has invested in companies such as Epizyme,[1] Intarcia Therapeutics,[8][9] Aerie Pharmaceuticals,[10] Muse Bio[11] and Universal American,[5] Foresite has funded 10x Genomics since its Series A round in November 2013 and led its Series B round in January 2015, as well as its Series C round in March 2016.[12][13] In April 2014,[5] Foresite closed Foresite Capital Fund II, a $300 million fund.[18] Foresite Capital Fund III, a $450 million fund, was closed in July 2015.[14] Its investments include Editas Medicine[15] and Intarcia Therapeutics.[16] References1. ^1 2 {{cite news |url=http://www.xconomy.com/san-francisco/2015/07/29/foresite-capital-keeps-late-stage-healthcare-focus-with-450m-third-fund/#|title=Foresite Capital Keeps Late-Stage Healthcare Focus With $450M Third Fund|author=David Holley|date=29 July 2015|publisher=Xconomy|accessdate=20 May 2017}} {{US-finance-company-stub}}2. ^{{cite news |url=https://www.wsj.com/articles/DJFVW00020130131e91vs5ph2|title=Growth-Equity Firm Foresite Capital Raises $100M for Debut Health-Care Fund|author=Brian Gormley|date=31 January 2013|publisher=Wall Street Journal|accessdate=20 May 2017}} 3. ^{{cite news |url=http://www.fiercebiotech.com/venture-capital/foresite-capital-reloads-a-450m-biotech-venture-fund|title=Foresite Capital reloads with a $450M biotech venture fund|author=Damian Garde|date=29 July 2015|publisher=Fierce Biotech|accessdate=20 May 2017}} 4. ^{{cite news |url=http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/01/foresite-capital-jim-tananbaum.html|title=Foresite Capital raises $100M to invest in late-stage healthcare companies|date=31 January 2013|publisher=San Francisco Business Times|accessdate=20 May 2017}} 5. ^1 2 {{cite news |url=https://venturebeat.com/2017/05/01/dominos-taps-ifttt-to-deactivate-your-garden-sprinkler-when-your-pizzas-due-for-delivery/|title=Health care venture firm Foresite Capital closes $300M fund|author=Eric Blattberg|date=1 April 2014|publisher=Venture Beat|accessdate=20 May 2017}} 6. ^{{cite news |url=http://www.xconomy.com/boston/2013/11/06/karyopharm-prices-upsized-ipo-16-per-share-begins-trading-today/|title=Karyopharm Prices Upsized IPO at $16 Per Share, Begins Trading Today|author=Ben Fidler|date=6 November 2013|publisher=Xconomy|accessdate=20 May 2017}} 7. ^{{cite news |url=http://www.xconomy.com/san-francisco/2013/01/31/foresite-capital-closes-100m-fund-for-late-stage/|title=Foresite Capital Closes $100M Fund for Late-Stage Biotechs|author=Luke Timmerman|date=31 January 2013|publisher=Xconomy|accessdate=20 May 2017}} 8. ^{{cite news |url=http://fortune.com/2016/09/15/diabetes-unicorn-raises-final-vc-round-before-ipo/|title=Diabetes ‘Unicorn’ Raises Final VC Round Before IPO|author=Dan Primack|date=15 September 2016|publisher=Fortune|accessdate=20 May 2017}} 9. ^{{cite news |url=http://www.bizjournals.com/boston/blog/bioflash/2014/10/here-s-who-stands-to-gain-from-intarcia-s-success.html|title=Here’s who stands to gain from Intarcia’s success with a type 2 diabetes pump|date=2 October 2014|publisher=Boston Business Journal|accessdate=20 May 2017}} 10. ^{{cite news |url=http://www.barrons.com/articles/aerie-stock-hits-record-high-holder-sells-2-million-1476439448|title=Aerie Stock Hits Record High, Holder Sells $2 Million|author=Ed Lin|date=14 October 2016|publisher=Barrons|accessdate=20 May 2017}} 11. ^{{cite news |url=https://www.genomeweb.com/gene-silencinggene-editing/muse-bio-closes-23m-series-b-financing-round|title=Muse Bio Closes $23M Series B Financing Round|publisher=Genome Web|accessdate=20 May 2017}} 12. ^{{cite news |url=http://www.fiercebiotech.com/it/10x-genomics-scoops-another-55m-to-fuel-commercialization-of-long-read-tech|title=10X Genomics scoops another $55M to fuel commercialization of long-read tech|author=Nick Paul Taylor|date=21 March 2016|publisher=Fierce Biotech|accessdate=20 May 2017}} 13. ^{{cite news |url=http://www.xconomy.com/san-francisco/2015/01/12/10x-genomics-emerges-with-80m-and-toaster-sized-sequencer-upgrade/|title=10X Genomics Emerges With $80M and Toaster-Sized Sequencer Upgrade|author=Alex Lash|date=12 January 2015|publisher=Xconomy|accessdate=20 May 2017}} 14. ^1 {{cite news |url=http://www.fiercebiotech.com/venture-capital/foresite-banks-300m-to-bet-on-late-stage-biotechs|title=Foresite banks $300M to bet on late-stage biotechs|author=Damian Gards|date=1 April 2014|publisher=Fierce Biotech|accessdate=20 May 2017}} 15. ^{{Cite web|url=https://massinvestordatabase.com/publicfirm.php?name=Foresite+Capital|title=Foresite Capital - Massinvestor Venture Capital and Private Equity Database|website=massinvestordatabase.com|access-date=2019-02-27}} 16. ^{{Cite web|url=https://www.vcnewsdaily.com/Intarcia%20Therapeutics/venture-funding.php|title=Intarcia Therapeutics Venture Capital and Private Equity Financings|website=www.vcnewsdaily.com|access-date=2019-02-27}} 2 : Venture capital firms of the United States|American companies established in 2011 |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。